News Update

Jan 01, 2002
Pharmaceutical Executive
The wrangling over whether pharma companies invest more in R&D than in marketing is heating up again.
Jan 01, 2002
Pharmaceutical Executive
Medical experts around the world warn that inappropriate use of Cipro (ciproflaxin) is only one aspect of the growing problem of bacterial resistance to treatment.
Jan 01, 2002
Pharmaceutical Executive
MICHIGAN-In an aggressive move to squeeze price discounts from the industry, Michigan recently released a list of pharmaceuticals, mostly generic and lower-priced,
Jan 01, 2002
Pharmaceutical Executive
For once, health activists and the pharma industry both welcomed a World Trade Organization declaration on Trade-Related Aspects of Intellectual Property Rights (TRIPS) and public health, but there is little doubt that it opens the way to further compulsory licensing and parallel imports.
Jan 01, 2002
Pharmaceutical Executive
One reason new medicines are more expensive is that the cost of discovering and producing new therapies is soaring.
Dec 01, 2001
Pharmaceutical Executive
York, UK-Pharma companies have failed to prevent product counterfeiting, and experts warn that the industry-wide security body has no coordinated approach to help.
Dec 01, 2001
Pharmaceutical Executive
London, UK-Insurance companies will be unable to use genetic test results to approve or deny claims for at least the next five years, following a new agreement between the British government and the Association of British Insurers. The move ensures that people can still get insurance coverage whether or not they have had a test.
Dec 01, 2001
Pharmaceutical Executive
Brussels, Belgium-Pfizer believes the dual pricing system it introduced in Spain complies with Spanish and European Union competition laws, but the European Commission isn't so sure. Competition policy commissioner Mario Monti says the EC will scrutinize Pfizer's pricing policy, which is intended to prevent parallel trade out of low-cost Spain.
Dec 01, 2001
Pharmaceutical Executive
Tokyo, Japan-European pharma industry leaders have called for the opening of the Japanese market through measures to promote greater innovation there. The demand followed a European Federation of Pharmaceutical Industries and Associations' visit to Japan led by EFPIA president Jean-Frany}ois Dehecq, chairman and CEO of Sanofi-Synthelabo.
Dec 01, 2001
Pharmaceutical Executive
Washington, DC-More countries are hosting pharma's R&D efforts, creating a research environment ripe for abuses of patient safety because FDA cannot ensure the same protection in foreign trials as in domestic ones. A recent study by the US Health and Human Service's office of the inspector general (OIG) found that regions with less research experience-including Eastern Europe, Latin America, and East Asia-have become more desirable locations for US-based companies and contract research organizations' clinical trials. In fact, the number of countries producing data for FDA submissions jumped from 28 to 79 between 1989 and 1999. And that trend shows no
native1_300x100
lorem ipsum